Local miscommunications between glomerular cells as potential therapeutic targets for crescentic glomerulonephritides
- 10 April 2019
- journal article
- research article
- Published by JLE in Nephrologie & Therapeutique
- Vol. 15, S1-S5
Abstract
Necrotizing and crescentic rapidly progressive glomerulonephritis or crescentic glomerulonephritis is one of the severest forms of acquired glomerular diseases with significant mortality. Risk of end-stage renal failure at 5 years is near 30%, with a number of patients developing chronic kidney disease. Currently, autoimmune crescentic glomerulonephritides are treated with broad-spectrum immunosuppression inducing remission of the injury in the majority of patients. However, treatment is associated with significant side effects and by the time remission is achieved the majority of patients have developed renal tissue damage and significant impairment of their kidney function with a steep slope of deterioration within the first weeks following initiation of immunosuppression. It is therefore important to develop complementary strategies that would be immediately active on the common process of destructive epithelial processes. We have worked to identify the major cellular pathways contributing to glomerular destruction in this context by a systematic comparison of patient tissues and experimental models. Our studies demonstrate the pivotal role of local intra- and intercellular communications in orchestrating the global glomerular tolerance to a severe rapidly progressive glomerulonephritis model with excellent anatomoclinical correlative expressions in kidney biopsies of individuals diagnosed with crescentic glomerulonephritis, irrespectively of the causal immune disorder. We hope that such approaches deciphering mechanisms of cellular adaptation that underlie kidney damage control in response to vasculitides, integrating both stress and damage responses, will delineate novel complementary therapies.Keywords
Funding Information
- Seventh Framework Programme
- European Research Council (107037)
- Agence Nationale de la Recherche
- Seventh Framework Programme
- Institut National de la Santé et de la Recherche Médicale
This publication has 53 references indexed in Scilit:
- PPARγ as a therapeutic target in diabetic nephropathy and other renal diseasesCurrent Opinion in Nephrology and Hypertension, 2012
- Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritisNature Medicine, 2011
- Complete remission of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibodyRheumatology, 2011
- Protective effects of PPAR agonist in acute nephrotic syndromeNephrology Dialysis Transplantation, 2011
- Deletion of PPAR-γ in immune cells enhances susceptibility to antiglomerular basement membrane diseaseJournal of Inflammation Research, 2010
- Tracing the Origin of Glomerular Extracapillary Lesions from Parietal Epithelial CellsJournal of the American Society of Nephrology, 2009
- Podocytes Contribute to the Formation of Glomerular CrescentsJournal of the American Society of Nephrology, 2008
- PPARγ in human and mouse physiologyBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2007
- Anti‐interleukin‐6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosusImmunology, 2006
- Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in ratsKidney International, 2001